CURRENT AND EMERGING MARKETS FOR NEUROLOGIC TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS

131 Pages | 19 Exhibits | 2010 Analysis | Forecasts Through 2019

OVERVIEW:
This new report from Medtech Insight analyzes the market for tissue engineering products for neurology indications. The potential United States (U.S.) market for tissue engineering products for neurology applications is substantial, with some segments representing multibillion-dollar opportunities. In the U.S., the total potential market for these products is expected to exceed $13.6 billion in the year 2019.

Market segments covered by this report include tissue engineering and cell transplantation products for the treatment of neurologic diseases/disorders including Alzheimer's disease, epilepsy, Huntington's disease, multiple sclerosis, Parkinson's disease, peripheral nerve regeneration, spinal cord injury, and stroke. A variety of tissue engineering approaches show promise for treating diseases and disorders of the central nervous system, and many companies are developing product candidates for the U.S. market based on several technologies including gene therapy, growth factors, monoclonal antibodies, nerve grafting, and stem cells.

In addition, this report includes an overview of some of the most prevalent neurologic disorders and diseases in the U.S. as well as an analysis of emerging competitors and products/technologies that currently are under development.

This Medtech Insight report is the third in a series of reports covering U.S. tissue engineering markets. Upcoming reports in this series will provide analyses of U.S. markets for tissue-engineered products for organ regeneration, skin replacement, and urology applications.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. The Nervous System
ii. Neurologic and Other Diseases/Disorders
	a. Alzheimer's Disease
	b. Amyotrophic Lateral Sclerosis
	c. Epilepsy
	d. Multiple Sclerosis
	e. Parkinson's Diseases
	f. Stroke
iii. Tissue Engineering Technologies
	a. Biomaterials
	b. Cell Culture Technology
	c. Stem Cell Technology
	d. Immunoisolation Technology
iv. Current and Emerging Markets for Neurologic Tissue Engineering and Cell Transplantation Products
	a. Gene Therapy
	b. Growth Factors
	c. Nerve Grafting
	d. Stem Cell-Based Therapies
	e. Other Tissue Engineering Technologies
	f. Market Analysis
v. Methodology

Exhibit ES-1: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019

1. OVERVIEW OF THE NERVOUS SYSTEM AND SELECTED NEUROLOGIC DISEASES/DISORDERS

1.1 The Nervous System
	1.1.1 Sacral Nerves
	1.1.2 Vagus Nerves
	1.1.3 Neurons
	1.1.4 The Brain
	1.1.5 The Spine
1.2 Neurologic and Other Diseases/Disorders
	1.2.1 Alzheimer's Disease
		1.2.1.1 Etiology
		1.2.1.2 Epidemiology
	1.2.2 Amyotrophic Lateral Sclerosis
		1.2.2.1 Etiology
		1.2.2.2 Epidemiology
	1.2.3 Epilepsy
		1.2.3.1 Etiology
		1.2.3.2 Epidemiology
	1.2.4 Multiple Sclerosis
		1.2.4.1 Etiology
		1.2.4.2 Epidemiology
	1.2.5 Parkinson's Disease
		1.2.5.1 Etiology
		1.2.5.2 Epidemiology
	1.2.6 Stroke
		1.2.6.1 Etiology
		1.2.6.2 Epidemiology

Exhibit 1-1: United States Population, by Age Group, Selected Years, 2000-2050
Exhibit 1-2: The Sacral Nervous System
Exhibit 1-3: The Vagus Nerve
Exhibit 1-4: Anatomy of the Brain
Exhibit 1-5: Anatomy of a Spinal Segment
Exhibit 1-6: Alzheimer's Disease, Facts and Figures
Exhibit 1-7: Amyotrophic Lateral Sclerosis, Facts and Figures
Exhibit 1-8: Epilepsy, Facts and Figures
Exhibit 1-9: Multiple Sclerosis, Facts and Figures
Exhibit 1-10: Parkinson's Disease, Facts and Figures
Exhibit 1-11: Stroke, Facts and Figures

2. TISSUE ENGINEERING AND ORGAN REGENERATION TECHNOLOGIES

2.1 Biomaterials
	2.1.1 Synthetic Biomaterials
	2.1.2 Biologically Derived Biomaterials
		2.1.2.1 Collagen
		2.1.2.2 Xenogeneic Tissue
	2.1.3 Hybrid Biomaterials
	2.1.4 Genetically Engineered Biomaterials
		2.1.4.1 Deoxyribonucleic Acid Transfection Vectors
		2.1.4.2 Genetically Manipulated Cells
		2.1.4.3 Three-Dimensional Polymer Technology
		2.1.4.4 Transgenics
		2.1.4.5 Fibroblasts
		2.1.4.6 Immortalized Neural Stem Cells
		2.1.4.7 Gene-Activated Matrices
	2.1.5 Scaffolds
	2.1.6 Vascular Grafts
2.2 Cell Culture Technology
	2.2.1 Bioreactors
		2.2.1.1 Flatbed Perfusion Systems
		2.2.1.2 Hollow Fiber Bioreactor Systems
		2.2.1.3 Cell Suspension Systems
		2.2.1.4 Disposable Bioreactors
2.3 Stem Cell Technology
	2.3.1 Cell Extraction and Expansion
	2.3.2 Bioreactors
2.4 Immunoisolation Technology
	2.4.1 Chimeric Immunity
	2.4.2 Cell Encapsulation Technology

Exhibit 2-1: 2010, Selected Synthetic Biomaterials Used in Tissue Engineering
Exhibit 2-2: 2010, Selected Natural Biomaterials Used in Tissue Engineering
Exhibit 2-3: 2010, Selected Current and Emerging Cell Extraction, Expansion, and Separation Products and Technologies

3. CURRENT AND EMERGING MARKETS FOR NEUROLOGIC TISSUE ENGINEERING AND CELL TRANSPLANTATION PRODUCTS

3.1 Gene Therapy
	3.1.1 Ceregene
	3.1.2 Genzyme
	3.1.3 Isis Pharmaceuticals
3.2 Growth Factors
	3.2.1 Acorda Therapeutics
	3.2.2 Alseres Pharmaceuticals
	3.2.3 NeuroNova in collaboration with Medtronic
	3.2.4 The Parkinson Study Group
3.3 Nerve Grafting
	3.3.1 AxoGen
	3.3.2 Integra LifeSciences
3.4 Peptides
	3.4.1 CellMed/Biocompatibles International
3.5 Remyelinating Monoclonal Antibodies
	3.5.1 Acorda Therapeutics
3.6 Stem Cell-Based Therapies
	3.6.1 Human Adult Stem Cells
		3.6.1.1 BrainStorm Cell Therapeutics
		3.6.1.2 NeuroNova
		3.6.1.3 ReNeuron
	3.6.2 Human Embryonic Stem Cells
		3.6.2.1 Geron
	3.6.3 Fetal Neural Stem Cells
		3.6.3.1 Neuralstem
		3.6.3.2 StemCells
	3.6.4 Fetal Porcine Cells
	3.6.5 Nasal Cavity-Derived Stem Cells
	3.6.6 Skin-Derived Stem Cells
3.7 Retinal Pigmented Epithelial Cell Transplants
	3.7.1 Titan Pharmaceuticals in collaboration with Bayer
3.8 Market Analysis
	3.8.1 Market Drivers
	3.8.2 Market Limiters
3.9 Competitive Analysis

Exhibit 3-1: 2010, Selected Tissue-Engineered/Regeneration Products for Neurology Applications
Exhibit 3-2: Tissue-Engineered Neurology Products, Potential Market Forecast, 2009 and 2019
Exhibit 3-3: Technologies for Neurologic Tissue Engineering, by Indication, 2009 and 2019
Exhibit 3-4: Technologies for Tissue Engineering and Cell Transplantation, Product Introduction Forecast, by Indication, 2014 and 2019

4. COMPANY PROFILES

4.1 Acorda Therapeutics, Inc.
4.2 AxoGen, Inc.
4.3 Ceregene, Inc.
4.4 Genzyme Corporation
4.5 Geron Corporation
4.6 Integra LifeSciences Corporation
4.7 Isis Pharmaceuticals, Inc.
4.8 Neuralstem, Inc.
4.9 NeuroNova AB
4.10 ReNeuron Group PLC

APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Acorda Therapeutics, Inc.
  2. AxoGen, Inc.
  3. Ceregene, Inc.
  4. Genzyme Corporation
  5. Geron Corporation
  6. Integra LifeSciences Corporation
  7. Isis Pharmaceuticals, Inc.
  8. Neuralstem, Inc.
  9. NeuroNova AB
  10. ReNeuron Group PLC
Contact Us

Need help finding medtech research? Let us help you!